Northern Trust Corp Has $86.77 Million Stake in Glaukos Co. (NYSE:GKOS)

Northern Trust Corp grew its position in Glaukos Co. (NYSE:GKOS - Free Report) by 7.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 578,673 shares of the medical instruments supplier's stock after buying an additional 40,052 shares during the period. Northern Trust Corp owned 1.05% of Glaukos worth $86,766,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. William Blair Investment Management LLC bought a new stake in Glaukos during the 4th quarter worth about $121,390,000. Alliancebernstein L.P. raised its position in shares of Glaukos by 1,235.4% during the 4th quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock valued at $122,374,000 after acquiring an additional 755,035 shares during the last quarter. Norges Bank acquired a new position in shares of Glaukos in the 4th quarter valued at $84,490,000. Gilder Gagnon Howe & Co. LLC boosted its position in shares of Glaukos by 25.3% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock worth $123,742,000 after purchasing an additional 166,677 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of Glaukos by 266.2% during the fourth quarter. Voya Investment Management LLC now owns 200,698 shares of the medical instruments supplier's stock worth $30,093,000 after purchasing an additional 145,890 shares during the period. Institutional investors own 99.04% of the company's stock.

Insider Buying and Selling at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Glaukos Stock Down 0.7 %

Shares of Glaukos stock traded down $0.60 on Friday, reaching $89.94. 511,969 shares of the company were exchanged, compared to its average volume of 682,126. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $94.87 and a 200 day moving average of $127.33. The company has a market capitalization of $5.14 billion, a price-to-earnings ratio of -31.34 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The company had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company's quarterly revenue was up 24.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.70) EPS. On average, equities research analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of recent analyst reports. Mizuho reduced their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Piper Sandler decreased their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, April 15th. Wells Fargo & Company cut Glaukos from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. Needham & Company LLC cut their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, Truist Financial reissued a "buy" rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.